Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17966487 | 0.92 | SMN1; SMN2 (0.40) | ALOX15KDM4EGAASMN1; SMN2L3MBTL1 | |
| SCHEMBL17966551 | 0.87 | JAK2 (0.39) | ALOX15KDM4EGAASMN1; SMN2L3MBTL1 | |
| SCHEMBL17966494 | 0.85 | SMN1; SMN2 (0.42) | ALOX15SMN1; SMN2L3MBTL1RAB9ALMNA | |
| SCHEMBL17966595 | 0.83 | GAA (0.41) | KDM4EGAASMN1; SMN2L3MBTL1HDAC3 | |
| SCHEMBL17966530 | 0.82 | KDM4E (0.43) | KDM4EGAASMN1; SMN2L3MBTL1HDAC3 | |
| SCHEMBL16065101 | 0.82 | L3MBTL1 (0.62) | SMN1; SMN2L3MBTL1RAB9ANPC1POLB | |
| SCHEMBL15401989 | 0.81 | L3MBTL1 (0.46) | KDM4EGAASMN1; SMN2L3MBTL1HDAC3 | |
| SCHEMBL17966507 | 0.81 | HDAC3 (0.42) | KDM4EGAASMN1; SMN2L3MBTL1HDAC3 | |
| SCHEMBL17966566 | 0.81 | HDAC3 (0.42) | KDM4EGAASMN1; SMN2L3MBTL1HDAC3 | |
| SCHEMBL17966581 | 0.80 | L3MBTL1 (0.42) | KDM4EGAASMN1; SMN2L3MBTL1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253764-B1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-06-09 | — | — | EP | disclosed |
| CN-107849055-B | Macrocyclic compounds useful as IRAK1/4 inhibitors and uses thereof | 默克专利有限公司 | 2020-08-07 | — | — | CN | disclosed |
| US-9815836-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-11-14 | — | — | US | disclosed |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2017-09-28 | — | — | US | disclosed |
| US-9708324-B2 | Macrocyclic compounds as IRAK1/4 inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617282-B2 | Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases | BIOGEN MA INC. (US) | 2017-04-11 | — | — | US | disclosed |
| WO-2016127025-A1 | MACROCYCLIC COMPOUNDS AS IRAK1/4 INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | US | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN MA INC. (US) | 2016-01-07 | — | — | US | disclosed |
| WO-2014143672-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | BIOGEN IDEC MA INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002265-A1 | MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | IRAK4, IRAK1, IRAK2 | ALOX15 2299/4885KDM4E 697/4885GAA 4758/4885 |
| US-20160229856-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | IRAK4, IRAK1, IRAK2 | ALOX15 3955/4885KDM4E 162/4885GAA 2705/4885 |
| US-20170275284-A1 | Macrocyclic Compounds as IRAK1/4 Inhibitors and Uses Thereof | IRAK4, IRAK1, IRAK2 | ALOX15 3955/4885KDM4E 162/4885GAA 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.